Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

8046 Background: Panobinostat (PAN) is an oral pan-histone deacetylase inhibitor (pan-HDACi). Thymus and Activation-Regulated Chemokine (TARC) is a major mechanism by which Reed-Sternberg cells drive intra-tumoral accumulation of reactive cells. TARC levels decrease with HDACi in HL cell lines and reflect disease activity in patients (pts). In a pivotal HL study, PAN achieved durable responses in heavily pretreated relapsed/refractory pts after ASCT. Prospective analysis of cytokine/chemokine levels was done to identify biomarkers for disease activity and to assess correlation with treatment response to PAN. This presentation focuses on TARC analysis. Methods: PAN was administered 40 mg TIW, every week in 21-day cycles. Response was assessed every 2 cycles by CT/MRI scan. Blood was collected at screening, days 5, 8, and 15 of cycle 1, day 1 of cycles 2-4, and end of treatment. Milliplex Map Human Cytokine/Chemokine panel II (Millipore) was used to analyze TARC. Results: Of 129 treated pts, 74% had tumor r...